Exelixis (EXEL) Retained Earnings (2010 - 2026)
Exelixis (EXEL) posted quarterly Retained Earnings of -$215.8 million for Q2 2026, down 10836.02% year-over-year from N/an in Q2 2025, and down 180.87% quarter-over-quarter from -$76.8 million in Q1 2026.
Exelixis (EXEL) Retained Earnings (2010 - 2026) Analysis & Trends
Exelixis' Retained Earnings history runs 17 years deep, the most recent figure standing at -$215.8 million for Q2 2026.
- In Q2 2026, Retained Earnings fell 10836.02% year-over-year to -$215.8 million; the TTM figure through Apr 2026 stood at -$215.8 million (down 10836.02% YoY), while the FY2026 annual figure was -$76.8 million, up 22.12% from the prior year.
- Retained Earnings for Q2 2026 stood at -$215.8 million, down from -$76.8 million in the prior quarter.
- The five-year high for Retained Earnings was $2.6 billion in Q1 2023, with the low at -$258.9 million in Q1 2024.
- The 5-year median for Retained Earnings is $1.3 million (2025), against an average of $815.7 million.
- The sharpest annual moves came in 2023 and 2026: Retained Earnings surged 61486.23% in 2023, then slumped 10836.02% in 2026.
- Exelixis' Retained Earnings stood at -$14.5 million in 2022, then slumped by 1093.8% to -$173.4 million in 2023, then surged by 1462.25% to $2.4 billion in 2024, then sank by 99.85% to $3.6 million in 2025, then sank by 6153.13% to -$215.8 million in 2026.
- Business Quant data shows EXEL's Retained Earnings at -$215.8 million in Q2 2026, -$76.8 million in Q1 2026, and $3.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | 2.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 2.11 Bn |
| Apr 3, 2026 | -215.79 Mn |
| Jan 2, 2026 | -76.83 Mn |
| Oct 3, 2025 | 3.57 Mn |
| Jul 4, 2025 | 1.35 Mn |
| Apr 4, 2025 | 2.01 Mn |
| Jan 3, 2025 | -98.65 Mn |
| Sep 27, 2024 | 2.36 Bn |
| Jun 28, 2024 | 2.32 Bn |
| Mar 29, 2024 | -258.95 Mn |
| Dec 29, 2023 | -173.35 Mn |
| Sep 29, 2023 | 2.49 Bn |
| Jun 30, 2023 | 2.53 Bn |
| Mar 31, 2023 | 2.56 Bn |
| Dec 30, 2022 | -14.52 Mn |
| Sep 30, 2022 | -4.05 Mn |
| Jul 1, 2022 | -8.92 Mn |
| Apr 1, 2022 | 2.45 Bn |
| Dec 31, 2021 | -758,000.00 |
| Oct 1, 2021 | -311.67 Mn |